External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>TG Therapeutics focuses on developing treatments for B-cell mediated diseases, including their flagship product Briumvi for Multiple Sclerosis</li><li>The company has a pipeline of other products such as Umbralisib, TG-1701, and TG-1801 in development</li><li>Briumvi is an anti-CD20 monoclonal antibody targeted at specific types of MS, showcasing the company's commitment to addressing unmet medical needs in the field</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

TG Therapeutics focuses on developing treatments for B-cell mediated diseases, including their flagship product Briumvi for Multiple SclerosisThe company has a pipeline of other products such as Umbralisib, TG-1701, and TG-1801 in developmentBriumvi is an anti-CD20 monoclonal antibody targeted at specific types of MS, showcasing the company's commitment to addressing unmet medical needs in the fieldThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Tg Therapeutics Inc (TGTX) - Thursday, Apr 11, 2024

United States

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tg Therapeutics (TGTX US)

Tg Therapeutics Inc (TGTX) - Thursday, Apr 11, 2024

TG Therapeutics focuses on developing treatments for B-cell mediated diseases, including their flagship product Briumvi for Multiple Sclerosis The...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)